Pomacel 2mg capsule - Pomalidomide | Myapplepharma

Pomacel 2mg is a Glenmark Pharmaceuticals product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide.
Pomacel 2mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as;
Immuno modulatory
Anti-angiogenesis
Anti-neoplastic
Pomacel 2mg is like thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may lead to severe liver injury.

INDICATION

The major therapeutic indication of Pomacel 2mg is involved in the treatment of multiple myeloma. This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomacel 2mgomide.
Pomacel 2mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.

DOSAGE & ADMINISTRATION

The prescribed dose of Pomacelin multiple myeloma is 4mg should be administered orally as once a day on day 1 to 21 of reciprocated 28-day cycles.
Pomacel 2mg should be concomitant with dexamethasone.
Pomacel 2mg Capsules should be taken with or without food.
During hematological toxicities:
Neutropenia;
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomaceltherapy and provide CBC weekly
ANC more than or equal to 500/mcl: Continue the Pomacel 3mg daily.

WORK AS

Pomacel 2mg exhibits various activities like;
Anti-neoplastic activity:
Prohibits proliferation
Promote apoptosis of hematopoietic cancer cells
Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis

WARNING

There are two major worsening condition may occur during the treatment using with Pomacel 2mg.

Embryo fetal damage :

Pomacel 2mg Capsules are contraindicated to pregnancy period.
During the treatment, patients avoid to becoming pregnant.
Use effective contraceptives for preventing pregnancy during therapy.

DRUG INTERACTION

Pomalidomide metabolism is mediated by CYP1A2 & CYP3A4.
The concomitant use of Pomacel 2mg with CYP1A2 drugs like Fluvoxamine causes elevation of Cmax& AUC of Pomalidomide and concludes as increased concentration of Pomacelleads to higher extent of adverse effects associated with Pomalid
In this condition, reduce the dose of Pomacel 2mg and recommended.

SIDE EFFECTS

More common effects of Pomacel 2mg :
If taken during pregnancy, Severe life-threatening human birth defects
Fatigue
Weakness
Low white blood cell count
Anemia
Constipation
Nausea
Diarrhea
Shortness of breath
Upper respiratory infections
Back pain
Fever.

Pomyelo 2mg capsule - Pomalidomide | Myapplepharma

Pomyelo 2mg is a product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide.
Pomyelo 2mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as;
Immuno modulatory
Anti-angiogenesis
Anti-neoplastic
Pomyelo 2mg is like thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment.
This may lead to severe liver injury.
Pomyelo 2mg is involved in the treatment for regression & unmanageable multiple myeloma.
Pomyelo 2mg is used in the patients who are failing to response for Lenalidomide treatment.
Pomyelo 2mg is used in combination with dexamethasone.

INDICATION

The major therapeutic indication of Pomyelo 2mg is involved in the treatment of multiple myeloma.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomyelo 2mg.
Pomyelo 2mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.

DOSAGE & ADMINISTRATION

Pomyelo 2mg should be concomitant with dexamethasone.
Pomyelo 2mg capsules should be taken with or without food.
During hematological toxicities:

Neutropenia:

ANC (absolute neutrophils count) <500/mcl: Postpone the Pomyelo therapy and provide CBC weekly
ANC more than or equal to 500/mcl: Continue the Pomyelo3mg daily.

Thrombocytopenia:

Platelets count <25,000/mcL: postpone the Pomyelo treatment & follow the CBC
>50,000/mcL: continue 3mg of Pomyelo
Pomyelo 2mg with potent CYP1A2 inhibitor:
During this combination reduce the dose of Pomyelo by 50%

WARNING

There are two major worsening condition may occur during the treatment using with Pomyelo 2mg.

Embryo fetal damage:

Pomyelo 2mg capsules are contraindicated to pregnancy period.
During the treatment, patients avoid to becoming pregnant.
Use effective contraceptives for preventing pregnancy during therapy.

WORK AS

Pomyelo 2mg exhibits various activities like;

Immuno modulatory:

Boosted the T-cells & natural killer cell mediate immunity.
The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.

Anti-angiogenesis:

Interfere with formation of new vessels and leads to inhibit the cell division.

SIDE EFFECTS

More common effects :

If taken during pregnancy, Severe life-threatening human birth defects
Fatigue
Weakness
Low white blood cell count
Anemia
Constipation
Nausea

Pomalid 1mg capsules (pomalidomide) - Buy Pomalid 1mg capsules Online at best Price in India -apple pharmaceuticals

Pomalid (pomalidomide) 1mg is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called pomalidomide. Pomalid(pomalyst) 1mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomalid(pomalidomide) 1mg is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury.Pomalid(pomalyst) 1mg is involved in the treatment for regression & unmanageable multiple myeloma.Pomalid(pomalidomide) 1mg is used in the patients who are failing to response for Lenalidomide treatment.Pomalid(pomalyst) 1mg is used in combination with dexamethasone.

INDICATION

The major therapeutic indication of Pomalid(pomalidomide) 1mg is involved in the treatment of multiple myeloma.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalid(pomalyst) 1mg
Pomalid(pomalidomide) 1mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.

pomalid 1mg capsule 

DOSAGE & ADMINISTRATION

During hematological toxicities;

Neutropenia :

ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalid therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomalid 3mg daily.

Thrombocytopenia :

Platelets count <25,000/mcL: postpone the Pomalid capsule treatment & follow the CBC >50,000/mcL: continue 3mg of Pomalid capsule
Pomalid(pomalidomide) 1mg with potent CYP1A2 inhibitor :
During this combination reduce the dose of Pomalid by 50%

In renal impairment :

Initial dose of Pomalid(pomalidomide) is 3mg

In hepatic impairment :

Mild to moderate condition, an initial dose of Pomalid(pomalyst) is 3mg; in severe condition, the initial dose of Pomalid(pomalidomide) is 2mg.

POMALID 1MG WORKS

Pomalid(pomalyst) 1mg exhibits various activities like;
Anti-neoplastic activity

Prohibits proliferation Promote apoptosis of hematopoietic cancer cells Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis
Immuno modulatory

Boosted the T-cells & natural killer cell mediate immunity. The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.
Anti-angiogenesis

Interfere with formation of new vessels and leads to inhibit the cell division.

WARNING

There are two major worsening condition may occur during the treatment using with Pomalid(pomalidomide) 1mg.
Embryo fetal damage

Pomalid(pomalyst) 1mg capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy.
Venous & arterial thromboembolism

Patient who are receiving Pomalid(pomalidomide)1mg capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke. This type of condition should be treated by initiating prophylactic anti-thrombotic drugs. The patients who are acquiring this condition then thromboprophylaxis should be provided

DRUG INTERACTION

Pomalidomide(pomalyst) metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomalid 1mg with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomalidomide and concludes as increased concentration of Pomalid capsule leads to higher extent of adverse effects associated with Pomalid In this condition, reduce the dose of Pomalid(pomalidomide) 1mg and recommended.

POMALID 1mg

Pomalid (pomalidomide) 1mg is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called pomalidomide. Pomalid(pomalyst) 1mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomalid(pomalidomide) 1mg is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury. Pomalid(pomalyst) 1mg is involved in the treatment for regression & unmanageable multiple myeloma. Pomalid(pomalidomide) 1mg is used in the patients who are failing to response for Lenalidomide treatment.Pomalid(pomalyst) 1mg is used in combination with dexamethasone.

INDICATION

The major therapeutic indication of Pomalid(pomalidomide) 1mg is involved in the treatment of multiple myeloma.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalid(pomalyst) 1mg
Pomalid(pomalidomide) 1mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.

DOSAGE & ADMINISTRATION

During hematological toxicities;

Neutropenia :

ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalid therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomalid 3mg daily.

Thrombocytopenia :

Platelets count <25,000/mcL: postpone the Pomalid treatment & follow the CBC >50,000/mcL: continue 3mg of Pomalid
Pomalid(pomalidomide) 1mg with potent CYP1A2 inhibitor :
During this combination reduce the dose of Pomalid by 50%

In renal impairment :

Initial dose of Pomalid(pomalidomide) is 3mg

In hepatic impairment :

Mild to moderate condition, an initial dose of Pomalid(pomalyst) is 3mg; in severe condition, the initial dose of Pomalid(pomalidomide) is 2mg.

POMALID 1MG WORKS

Pomalid(pomalyst) 1mg exhibits various activities like;
Anti-neoplastic activity

Prohibits proliferation Promote apoptosis of hematopoietic cancer cells Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis
Immuno modulatory

Boosted the T-cells & natural killer cell mediate immunity. The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.
Anti-angiogenesis

Interfere with formation of new vessels and leads to inhibit the cell division.

WARNING

There are two major worsening condition may occur during the treatment using with Pomalid(pomalidomide) 1mg.
Embryo fetal damage

Pomalid(pomalyst) 1mg capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy.
Venous & arterial thromboembolism

Patient who are receiving Pomalid(pomalidomide)1mg capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke. This type of condition should be treated by initiating prophylactic anti-thrombotic drugs. The patients who are acquiring this condition then thromboprophylaxis should be provided

DRUG INTERACTION

Pomalidomide(pomalyst) metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomalid 1mg with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomalidomide and concludes as increased concentration of Pomalid leads to higher extent of adverse effects associated with Pomalid In this condition, reduce the dose of Pomalid(pomalidomide) 1mg and recommended.

                                       Pomalid 4mg 

Pomalid (pomalidomide)4mg is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called pomalidomide. Pomalid(pomalyst) 4mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomalid(pomalidomide) 4mg is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury.Pomalid 4mg is involved in the treatment for regression & unmanageable multiple myeloma. Pomalid(pomalidomide) 4mg is used in the patients who are failing to response for Lenalidomide treatment. Pomalid(pomalyst) 4mg is used in combination with dexamethasone.

INDICATION

The major therapeutic indication of Pomalid(pomalidomide) 4mg is involved in the treatment of multiple myeloma. This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalid 4mgomide. Pomalid 4mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.
During hematological toxicities

Neutropenia :

ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalid therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomalid 3mg daily.

Thrombocytopenia :

Platelets count <25,000/mcL: postpone the Pomalid treatment & follow the CBC >50,000/mcL: continue 3mg of Pomalid
Pomalid(pomalidomide) 4mg with potent CYP1A2 inhibitor :
During this combination reduce the dose of Pomalid by 50%

In renal impairment :

Initial dose of Pomalid(pomalyst) is 3mg

In hepatic impairment :

Mild to moderate condition, an initial dose of Pomalid is 3mg; in severe condition, the initial dose of Pomalid is 2mg.
Pomalid(pomalidomide) 4mg WORKS

Pomalid 4mg exhibits various activities like;
Anti-neoplastic activity

Prohibits proliferation Promote apoptosis of hematopoietic cancer cells Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis
Immuno modulatory

Boosted the T-cells & natural killer cell mediate immunity. The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.
Anti-angiogenesis

Interfere with formation of new vessels and leads to inhibit the cell division.

WARNING

There are two major worsening condition may occur during the treatment using with Pomalid(pomalidomide) 4mg.
Embryo fetal damage

Pomalid(pomalyst) 4mg capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy.
Venous & arterial thromboembolism

Patient who are receiving Pomalid(pomalidomide) 4mg capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke. This type of condition should be treated by initiating prophylactic anti-thrombotic drugs. The patients who are acquiring this condition then thromboprophylaxis should be provided

CONTRAINDICATION

Pomalid(pomalidomide) 4mg should be contraindicated to pregnancy & lactating women. The pregnancy category of Pomalid 4mg is X.

DRUG INTERACTION

Pomalidomide metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomalid 4mg with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomalidomide and concludes as increased concentration of Pomalid leads to higher extent of adverse effects associated with Pomalid In this condition, reduce the dose of Pomalid(pomalidomide) 4mg and recommended.

                                        Pomalong 1mg

Pomalong 1mg is a Sun Pharmaceuticals product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide.
Pomalong 1mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as;
Immuno modulatory
Anti-angiogenesis
Anti-neoplastic
Pomalong 1mg is like thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment.
This may lead to severe liver injury.
Pomalong 1mg is involved in the treatment for regression & unmanageable multiple myeloma.
Pomalong 1mg capsule is used in the patients who are failing to response for Lenalidomide treatment.
Pomalong 1mg is used in combination with dexamethasone.

INDICATION

The major therapeutic indication of Pomalong 1mg capsule  is involved in the treatment of multiple myeloma.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalong 1mg omide.
Pomalong 1mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.

DOSAGE & ADMINISTRATION

The prescribed dose of Pomalong in multiple myeloma is 4mg should be administered orally as once a day on day 1 to 21 of reciprocated 28-day cycles.
Pomalong 1mg should be concomitant with dexamethasone.
Pomalong 1mg Capsules should be taken with or without food.
During hematological toxicities:

Neutropenia:

ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalong therapy and provide CBC weekly
ANC more than or equal to 500/mcl: Continue the Pomalong 3mg daily.

Thrombocytopenia:

Platelets count <25,000/mcL: postpone the Pomalong treatment & follow the CBC
>50,000/mcL: continue 3mg of Pomalong
Pomalong 1mg with potent CYP1A2 inhibitor:
During this combination reduce the dose of Pomalong by 50%

In renal impairment:

Initial dose of Pomalong is 3mg

In hepatic impairment:

Mild to moderate condition, an initial dose of Pomalong is 3mg; in severe condition, the initial dose of Pomalong is 2mg.

WORK AS

Pomalong 1mg exhibits various activities like;

Anti-neoplastic activity:

Prohibits proliferation
Promote apoptosis of hematopoietic cancer cells
Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis

Immuno modulatory:

Boosted the T-cells & natural killer cell mediate immunity.
The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.

Anti-angiogenesis:

Interfere with formation of new vessels and leads to inhibit the cell division.

WARNING

There are two major worsening condition may occur during the treatment using with Pomalong 1mg.

Embryo fetal damage :

Pomalong 1mg Capsules are contraindicated to pregnancy period.
During the treatment, patients avoid to becoming pregnant.
Use effective contraceptives for preventing pregnancy during therapy.

Venous & arterial thromboembolism :

Patient who are receiving Pomalong 1mg Capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke.
This type of condition should be treated by initiating prophylactic anti-thrombotic drugs.
The patients who are acquiring this condition then thromboprophylaxis should be provided

DRUG INTERACTION

Pomalidomide metabolism is mediated by CYP1A2 & CYP3A4.
The concomitant use of Pomalong 1mg with CYP1A2 drugs like Fluvoxamine causes elevation of Cmax& AUC of Pomalidomide and concludes as increased concentration of Pomalong leads to higher extent of adverse effects associated with Pomalid
In this condition, reduce the dose of Pomalong 1mg and recommended.

CONTRAINDICATION

Pomalong 1mg should be contraindicated to pregnancy & lactating women. The pregnancy category of Pomalong 1mg is X.

SIDE EFFECTS

More common effects :

If taken during pregnancy, Severe life-threatening human birth defects
Fatigue
Weakness
Low white blood cell count
Anemia
Constipation
Nausea
Diarrhea
Shortness of breath
Upper respiratory infections
Back pain
Fever.
Less common effects :
Neuropathy
Dizziness
Confusion.